Search PubMed⌕ Search

Biomedical subjects

M Godin

Publications and source records attributed to M Godin.

159 records · Page 9Linked to original sources
PubMedDate not supplied

Evidence that an autoantibody of IgG3 subclass against C3b discloses a C3 Nef activity in a pateint with partial lipodystrophy and glomerulonephritis.

Immunoglobulins of IgG3 subclass were purified from the serum of a patient with partial lipodystrophy and glomerulonephritis. The immunochemical data clearly showed that the immunoglobulins were directed against newly-formed determinants on C3 molecule when activation of complement occurred. This autoantibody property was related to the C3 nephritis factor activity present in the serum of the patient. Furthermore, this serum was unable to destroy cell bound C3b. This result suggested that this patient would presented a deficiency of C3b inactivation system.

Adult↗
PubMedDate not supplied

Selective deficiencies in complement component : a family with hereditary C2 deficiency.

We report herein a new case of C2 deficiency in a patient with systemic lupus. The subject and one of her brothers, who shows no clinical manifestations, are hymozygous C2 deficient. All other family members are heterozygous for the C2 deficiency. Gene for C2 deficiency (C2d) was shown to be inherited with HLA-A9, B7/Bfs and HLA-A10, B27/Bfs haplotypes. This association has not previously been described.

Adolescent↗
PubMedDate not supplied

A perspective on di-2-ethyl-hexyphthalate in intravenous therapy.

Di-2-ethyl-hexyphthalate (DEHP) is a major component of polyvinyl chloride (PVC), which is the plastic of choice used to fabricate disposable medical devices. Most containers and tubings used to administer intravenous therapy are made with PVC, and DEHP controls the strength and pliability of these PVC products. Certain infusates have been shown to leach DEHP from plastic. The possibility of harmful effects to the human body is a concern, especially to infants and pregnant females. Carcinogenicity, hepatotoxicity, teratogenicity, and more recently, cardiotoxic effects have been documented, yet we continue to use these products that leach DEHP when alternatives are available. Exposure to this substance can be minimized with careful adherence to manufacturers' recommendations when administering substances that leach DEHP.

Diethylhexyl Phthalate↗